Fresh off a major clinical win, Revolution Medicines alleges that Erasca’s pancreatic cancer drug infringes on key patent ...
Erasca shares fell after Revolution Medicines alleged that the company's development of its ERAS-0015 cancer treatment infringes on existing patents and relies on stolen trade secrets.
The company has multiple drugs in its pipeline that could generate billions in revenue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results